Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target

$4.16

+0.06 (+1.46%)

(As of 09/18/2024 ET)

Zentalis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 10 Analyst Ratings

Based on 10 Wall Street analysts who have issued ratings for Zentalis Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Hold." Out of the 10 analysts, 7 have given a hold rating, and 3 have given a buy rating for ZNTL.

Consensus Price Target

$10.78
159.08% Upside

High Forecast	$20.00
Average Forecast	$10.78
Low Forecast	$4.00

According to the 10 analysts' twelve-month price targets for Zentalis Pharmaceuticals, the average price target is $10.78. The highest price target for ZNTL is $20.00, while the lowest price target for ZNTL is $4.00. The average price target represents a forecasted upside of 159.08% from the current price of $4.16.

Type	Current Forecast 9/20/23 to 9/19/24	1 Month Ago 8/21/23 to 8/20/24	3 Months Ago 6/22/23 to 6/21/24	1 Year Ago 9/20/22 to 9/20/23
Consensus Rating	Hold	Hold	Hold	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	7 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$10.78	$11.33	$11.33	$47.50
Forecasted Upside	159.08% Upside	113.30% Upside	93.77% Upside	110.66% Upside

Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)

Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.

Click here to see it because it’s a SHOCKER…

ZNTL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ZNTL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zentalis Pharmaceuticals Stock vs. The Competition

Type	Zentalis Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.30	2.77	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	159.08% Upside	1,010.31% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/16/2024	Oppenheimer 3 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $20.00	+424.93%
8/12/2024	Wedbush 3 of 5 stars	R. Driscoll Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$4.00	+33.33%
8/12/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00	+566.66%
6/20/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Merle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$28.00 ➝ $5.00	+20.77%
6/18/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$42.00 ➝ $6.00	+38.25%
6/18/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Equal Weight	$38.00 ➝ $8.00	+65.97%
Kamala Harris and The Woke Progressive Nightmare (Ad) New research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election Meltdown” coming this November. Click here now to see Jim’s shocking predictions for November.
6/18/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$32.00 ➝ $10.00	+107.47%
6/18/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Archila Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$29.00 ➝ $9.00	+40.62%
11/7/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
11/7/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$15.00	+20.19%
11/11/2022	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$55.00 ➝ $28.00	+35.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:30 AM ET.

ZNTL Forecast - Frequently Asked Questions

What is Zentalis Pharmaceuticals' forecast for 2024?: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Zentalis Pharmaceuticals is $10.78, with a high forecast of $20.00 and a low forecast of $4.00.
Should I buy or sell Zentalis Pharmaceuticals stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ZNTL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZNTL, but not buy additional shares or sell existing shares.
Does Zentalis Pharmaceuticals's stock price have much upside?: According to analysts, Zentalis Pharmaceuticals's stock has a predicted upside of 107.22% based on their 12-month stock forecasts.
Has Zentalis Pharmaceuticals been upgraded by Wall Street analysts recently?: Over the previous 90 days, Zentalis Pharmaceuticals's stock had 1 upgrade by analysts.
What analysts cover Zentalis Pharmaceuticals?: Zentalis Pharmaceuticals has been rated by research analysts at HC Wainwright, Oppenheimer, and Wedbush in the past 90 days.
Do Wall Street analysts like Zentalis Pharmaceuticals more than its competitors?: Analysts like Zentalis Pharmaceuticals less than other "medical" companies. The consensus rating for Zentalis Pharmaceuticals is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZNTL compares to other companies.